ARTL CFO discloses $11.03 stock options in ownership filing

Rhea-AI Filing Summary

Artelo Biosciences, Inc. (ARTL) reported the equity holdings of its Chief Financial Officer in a beneficial ownership statement. The filing lists two stock options to buy common stock, each with an exercise price of $11.03 per share. One option covers 5,000 shares of common stock and vests in equal monthly installments over four years starting from a vesting commencement date of January 1, 2025. The other option covers 2,500 shares of common stock, with half vesting on January 1, 2026 and the remaining half vesting on January 1, 2027, in each case contingent on continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Spring Mark Edward

(Last) (First) (Middle)

C/O ARTELO BIOSCIENCES, INC.,

505 LOMAS SANTA FE, SUITE 160

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/01/2025

3. Issuer Name and Ticker or Trading Symbol
ARTELO BIOSCIENCES, INC. [ ARTL ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	07/02/2035	Common Stock	5,000	$11.03	D
Stock Option (right to buy)	(2)	07/02/2035	Common Stock	2,500	$11.03	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date, such that the option shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean January 1, 2025.

2. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, fifty percent (50%) of the shares subject to the option shall vest January 1, 2026 and the remaining fifty percent (50%) of the shares subject to the option shall vest January 1, 2027.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Gregory D. Gorgas, as Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What type of SEC filing did ARTL submit for this insider ownership report?

This is a Section 16 beneficial ownership filing reporting the equity holdings of an officer of Artelo Biosciences, Inc. (ARTL), including stock options.

Who is the insider involved in this ARTL ownership filing and what is their role?

The reporting person is an officer of Artelo Biosciences, Inc. serving as Chief Financial Officer, and the filing reflects their beneficial ownership in company equity.

What stock options were reported by the ARTL Chief Financial Officer?

The Chief Financial Officer reported two stock options to buy common stock: one for 5,000 shares and another for 2,500 shares, each with an exercise price of $11.03 per share.

How does the 5,000-share ARTL stock option vest?

The 5,000-share option vests in 1/48th monthly installments starting from a vesting commencement date of January 1, 2025, becoming fully vested on the four-year anniversary, subject to continued service.

What is the vesting schedule for the 2,500-share ARTL stock option?

For the 2,500-share option, 50% of the shares vest on January 1, 2026 and the remaining 50% vest on January 1, 2027, conditioned on the officer continuing as a service provider.

What condition applies to vesting of the ARTL CFO stock options?

Both options vest only if the Chief Financial Officer continues to be a Service Provider as defined in Artelo Biosciences' 2018 Equity Incentive Plan through each applicable vesting date.